Formulation and evaluation of ficus glomerata mucilage sustained release matrix tablets of gliclazide

The main aim of present investigation was to develop sustained release matrix tablets of Gliclazide using fruit mucilage from the plant Ficus glomerata. Varying ratios of drug and polymer viz. 1:0.25, 1:0.5, 1:0.75, 1:1.0 and 1:1.25 were selected for the study. The flow properties of powdered mucilage and physical properties of matrix tablets were performed. The swelling behavior and release rate characteristics were studied. The in vitro drug release data was analyzed by zero order, first order, Higuchi plot, Peppas plot and Hixon-Crowell Models. It was observed that as the proportion of mucilage increased the release of drug from the matrix tablets was retarded. Stability studies were conducted at 40 +/- 2°C and RH 75 +/- 5% for 3 months indicates that Gliclazide was stable in the matrix tablets. The Differential Scanning Calorimetric [DSC] and Fourier Transform Infrared [FTIR] study revealed that there was no negative chemical interaction between drug and the mucilage used. From the dissolution study, it was concluded that dried Ficus glomerata mucilage can be used as an excipient for making sustained release matrix tablets

Pharmacokinetic difference of some generic tablet gliclazide 80 mg on Pakistani population

The goal of rational drug therapy is to produce a desired pharmacological response in an acceptable and predictable manner while minimizing the occurrence of undesired events. The Pharmacokinetics of different generics of tablet gliclazide 80 mg was investigated on healthy [10 x 2], Pakistani subjects. For this exploration an open-label, randomized, two-period crossover [Balanced in Complete Block Design] study, was conducted The out come of the said study suggests that all generics were found analogous regarding pharmacokinetic behavior in-spite of having different excipients, concentration of excipients, sources of raw material, manufacturing process, machinery, resources and also inter individual variation of the study. Results of the study also undoubtedly advocate that generics manufactured in different manufacturing units of Pakistan are near to the standard formulation and produce comparable results. No significant differences in pharmacokinetics parameters were observed, however, minor differences might narrate with inter individual variation in human volunteers and in different generic as well as different pharmaceutical unit

Gliclazide in the treatment of obese non-insulin dependent diabetic patients.

The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone. By day 20, the mean post prandial plasma glucose (PPG), and fasting plasma glucose (FPG) were significantly reduced from 276 +/- 13.5 to 195.8 +/- 13.9 mg % (p < 0.01) and 179 +/- 9.3 to 130.6 +/- 9.6 mg % (p < 0.01) respectively. This early glycaemic control was maintained, and by 3 months a further significant decrease occurred in PPG to 156.46 +/- 7.6 mg % (p < 0.01), and FPG to 106.9 +/- 3.8 mg % (p < 0.01). Mean glycosylated haemoglobin (HbA1c) was reduced from 10.3% to 7.7%. The drug had a favourable effect on serum lipids, significantly increasing high density lipoprotein fraction of cholesterol (HDL-C) (p < 0.034), and decreasing low density lipoprotein fraction of cholesterol (LDL-C) (p < 0.049). Mean body weight showed a significant reduction of 1.5 kg (p < 0.003). We conclude that gliclazide is an effective hypoglycaemic agent that ensures a rapid and sustained blood glucose control with a favourable effect on lipids and body weight in obese NIDDM patients.

Evaluación de la gliclazida como hipoglicemiante oral / Evaluation of glycazide as oral hypoglycemiant

Se estudiaron en total noventa y seis pacientes diabéticos tipo II, en su mayoría recién diagnosticados. Fueron suguidos durante un lapso de tres meses de tratamiento con gliclazida, después de un período de dieta de un mes sin obtener resultados satisfactorios en el control de la diabetes. La gliclazida se administró en la dosis de 80 a 240 mg. La glicemia en ayunas fue determinada al inicio del período de dieta, al comenzar el tratamiento con gliclazida, a las dos semanas (para reajustar la dosis) y luego al mes, dos y tres meses se seguir esta medicación. La hemoglobina glicosilada total se midío al inicio y al final del tratamiento. En ambos parámetros se encuentra un descenso significativo de los valores, lo cual muestra un resultado satisfactorio sobre el control de la diabetes. En las curvas de glicemia e insulinemia no se encuentran diferencias significativas antes y despues del período de dieta. En cambio, hay una mejoría importante de la tolerancia a la glucosa a los tres meses del tratamiento con la gliclazida. Hay también a los tres meses un incremento de la secreción de isulina estimulada por glucosa a los 15, 30 y 90 minutos, con valores prácticamente iguales en las tres etapas del estudio (ates de la dieta, antes de iniciar la gliclazida y a los tres meses de su administración) a las dos horas de la sobrecarga con glucosa. En lo que respecta a los lípidos plasmáticos, hay pocas variaciones con el tratamiento en los niveles de colestrol, colesterol-HDL y triglicéridos. Hubo buena tolerancia del medicamento

Estudo da gliclazide nos pacientes diabéticos näo insulino-dependentes / Gliclazide in non-insulin dependent diabetics

Trinta e um diabéticos declarados näo insulino-dependentes e näo equilibrados por regime alimentar exclusivo receberam, em média, durante três meses, 180mg diários de gliclazide, associada a um regime hipocalórico da ordem de 1.600 a 1.800 calorias por dia. Todos os parâmetros inicialmente alterados (glicemias em jejum e pós-prandial, hipertrigliceridemia, hipercolesterolemia, hemoglobina glicosilada) foram corrigidos de maneira importante e estatisticamente significativa. Näo houve interrupçäo de tratamento no decorrer do estudo, sendo muito satisfatória a aceitabilidade clínica e biológica

Tratamento do diabetes com a gliclazide / Treatment of diabetis with gliclazide

Os autores estudaram a eficácia hipoglicemiante da gliclazide sobre dois grupos de pacientes diabéticos näo insulino-dependentes: diabéticos que näo tinham recebido nenhum tratamento hipoglicemiante preliminar e doentes submetidos anteriormente a uma terapêutica hipoglicemiante oral. Observaram-se bons efeitos, tanto sobre os níveis de glicemia quanto nos valores dos triglicérides plasmáticos. Näo foi observado qualquer efeito colateral